History of allergic reactions attributed to compounds of similar chemical or biologic composition to ABT-888 or other agents used in study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to lenalidomide (i.e. thalidomide)
Patients must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to ABT-888, carboplatin, paclitaxel or other agents used in study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to vorinostat
History of allergic reactions attributed to compounds of similar chemical or biologic composition to veliparib or other agents used in study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to romidepsin, including cyclic tetrapeptide compounds
History of allergic reactions attributed to compounds of similar chemical or biologic composition to MLN8237, bortezomib or rituximab
Patients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to ABT-888 or other agents used in study, including Cremophor, carboplatin, paclitaxel, cisplatin, 5-fluorouracil, hydroxyurea, or any compounds of similar chemical or biologic composition are not eligible
History of allergic reactions attributed to compounds of similar chemical or biologic composition to AZD6244
History of allergic reactions attributed to compounds of similar chemical or biologic composition to cabozantinib (XL184)
Patients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to temozolomide or AZD1775 (MK-1775) are ineligible; the AZD1775 (MK-1775) investigator brochure and the temozolomide package insert can be referenced for more information
History of allergic reactions attributed to compounds of similar chemical or biologic composition to TRC102 or TMZ
History of allergic reactions attributed to compounds of similar chemical or biologic composition to XL184
History of allergic reactions attributed to compounds of similar chemical or biologic composition to CYT107
Patients must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to dabrafenib or other agents used in this study including dimethyl sulfoxide (DMSO)
Patients with history of allergic reactions attributed to compounds of similar chemical or biologic composition to belinostat, including hydroxamate compounds or arginine
Known severe hypersensitivity to selumetinib or any excipient of selumetinib or history of allergic reactions attributed to compounds of similar chemical or biologic composition to selumetinib
History of allergic reactions attributed to compounds of similar chemical or biologic composition to navitoclax, dabrafenib, or trametinib, or excipients or to dimethyl sulfoxide (DMSO)
History of allergic reactions attributed to compounds of similar chemical or biologic composition to pomalidomide (e.g. lenalidomide, thalidomide) or other agents used in study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to AZD 1775 (MK-1775) or gemcitabine
History of allergic reactions attributed to compounds of similar chemical or biologic composition to study drugs
History of allergic reactions attributed to compounds of similar chemical or biologic composition to study drugs; patients who have previously received either clofarabine or bortezomib will be excluded
Prior allergic reactions attributed to compounds of similar chemical or biologic composition to gemcitabine (gemcitabine hydrochloride) or cisplatin
Patients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to MLN0128 (TAK-228) are ineligible
History of allergic reactions attributed to compounds of similar chemical or biologic composition to navitoclax or sorafenib
History of allergic reactions attributed to compounds of similar chemical or biologic composition to MLN0128 (TAK-228) or ziv-aflibercept
History of allergic reactions attributed to compounds of similar chemical or biologic composition to MLN0128 or bevacizumab
History of allergic reactions attributed to compounds of similar chemical or biologic composition to ibrutinib or other agents used in study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to cabozantinib
History of allergic reactions attributed to compounds of similar chemical or biologic composition to MK-3475 and ziv-aflibercept
History of allergic reactions attributed to compounds of similar chemical or biologic composition to cabozantinib, nivolumab, ipilimumab or other agents used in study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to nivolumab
Patients must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to afatinib and/or cetuximab
History of allergic reactions attributed to compounds of similar chemical or biologic composition to talazoparib (BMN 673) or other agents used in study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to GDC-0449
History of allergic reactions attributed to compounds of similar chemical or biologic composition to sEphB4-HSA or other agents used in study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to MLN0128 (TAK-228)
History of allergic reactions attributed to compounds of similar chemical or biologic composition to TRC102 or pemetrexed and cisplatin
Patients with a history of allergic reactions attributed to compounds of similar composition to dolastatin or auristatin (e.g. Auristatin PHE, Auristatin PE, and symplostatin)
History of allergic reactions attributed to compounds of similar chemical or biologic composition to AZD1775 or belinostat
History of allergic reactions attributed to compounds of similar chemical or biologic composition to IPdR
Patient must NOT have a history of allergic reaction attributable to compounds of similar chemical or biologic composition to 18F-fluorothymidine
Patient must NOT have a history of allergic reaction attributable to compounds of similar chemical or biologic composition to 18F-FES
Known severe hypersensitivity to selumetinib or any excipient of selumetinib or history of allergic reactions attributed to compounds of similar chemical or biologic composition to selumetinib
Prior allergic reactions attributed to other monoclonal antibodies
History of allergic reactions attributed to compounds of similar chemical or biologic composition to MLN0128 (TAK-228)
Patients must NOT have a history of allergic reactions attributed to compounds of similar chemical or biochemical composition to cisplatin, carboplatin, etoposide, temozolomide or capecitabine
History of allergic reactions attributed to compounds of similar chemical or biologic composition to cediranib or olaparib
Patient does not have a known allergy to compounds of similar or biologic composition as triapine
History of clinically significant allergic reactions attributed to compounds of similar chemical or biologic composition to AT13387 or paclitaxel
History of allergic reactions attributed to compounds of similar chemical or biologic composition to MLN0128 (TAK-228)
History of allergic reactions attributed to compounds of similar chemical or biologic composition to cediranib or olaparib
History of allergic reactions attributed to compounds of similar chemical or biologic composition to onalespib or AT7519M
History of hypersensitivity attributed to compounds of similar chemical or biologic composition to MLN0128 (TAK-228) or osimertinib (AZD9291)
History of allergic reactions attributed to compounds of similar chemical or biologic composition to MEDI-570 or history of anaphylaxis to any biological component
History of allergic reactions attributed to compounds of similar chemical or biologic composition to methoxyamine or to pemetrexed or cisplatin
History of allergic reactions attributed to compounds of similar chemical or biologic composition to erlotinib and/or onalespib
History of allergic reactions attributed to compounds of similar chemical or biologic composition to lenalidomide and blinatumomab or other agents used in study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to VX-970, cisplatin, or gemcitabine
History of allergic reactions attributed to compounds of similar chemical or biologic composition to M6620 (VX-970) or cisplatin
History of allergic reactions attributed to compounds of similar chemical or biologic composition to AT13387 (onalespib)
History of allergic reactions attributed to compounds of similar chemical or biologic composition to ibrutinib (difficulty breathing, lip swelling, itching or rash)
History of allergic reactions attributed to compounds of similar chemical or biologic composition to VX-970
History of allergic reactions attributed to compounds of similar chemical or biologic composition to MK-3475 (pembrolizumab)
History of allergic reactions attributed to compounds of similar chemical or biologic composition to triapine or cisplatin
History of allergic reactions attributed to compounds of similar chemical or biologic composition to M6620 (VX-970) or gemcitabine
History of allergic reactions attributed to compounds of similar chemical or biologic composition to nivolumab
History of allergic reactions attributed to compounds of similar chemical or biologic composition to VX-970 or irinotecan
Patients must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to nivolumab
History of allergic reactions attributed to compounds of similar chemical or biologic composition to VX-970, carboplatin, gemcitabine or to these specific compounds
History of allergic reactions attributed to compounds of similar chemical or biologic composition to veliparib and MM-398; if patients have a history of allergic reactions to compounds resembling MM-398, they will be excluded from participating in the FMX MRI study, if applicable
History of allergic reactions attributed to compounds of similar chemical or biologic composition to nivolumab
History of allergic reactions attributed to compounds of similar chemical or biologic composition to nelfinavir
Patients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to LY2606368 or to its formulation are not eligible
History of allergic reactions attributed to compounds of similar chemical or biologic composition to dasatinib or ganitumab or other agents used in study
Known severe hypersensitivity to selumetinib or any excipient of selumetinib or history of allergic reactions attributed to compounds of similar chemical or biologic composition to selumetinib
History of allergic reactions attributed to compounds of similar chemical or biologic composition to selumetinib or other agents used in study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to olaparib and atezolizumab; patients with a known hypersensitivity to olaparib or any of the excipients of the product
History of allergic reactions attributed to compounds of similar chemical or biologic composition to nivolumab, ipilimumab, or blinatumomab
History of allergic reactions attributed to compounds of similar chemical or biologic composition to other agents used in study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to tremelimumab and MEDI4736 or previous toxicity attributed to MEDI4736 or other PD-1 or PD-L1 directed therapy that led to drug discontinuation
History of allergic reactions attributed to compounds of similar chemical or biologic composition to cediranib or olaparib
History of allergic reactions attributed to compounds of similar chemical or biologic composition to olaparib, cediranib, carboplatin, cisplatin, or etoposide
History of allergic reactions attributed to compounds of similar chemical or biologic composition to olaparib and AT13387 used in study
Patients with a history of allergic reactions attributed to compounds of similar composition, including macrolide and ketolide antibiotics, temsirolimus/other mTOR inhibitors, temozolomide or irinotecan are not eligible
History of allergic reactions attributed to compounds of similar chemical or biologic composition to bevacizumab or atezolizumab
History of allergic reaction attributed to compounds of similar or biologic composition to inotuzumab ozogamicin or other agents in the study
Known hypersensitivity to MK-3475 (pembrolizumab) or history of allergic reactions to compounds of similar chemical or biologic composition to anti-PD1 or PD-L1 antibodies or entinostat
History of allergic reactions attributed to compounds of similar chemical or biologic composition to AZD9291 (osimertinib) or bevacizumab
History of allergic reactions attributed to compounds of similar chemical or biologic composition to olaparib, cediranib or bevacizumab
Patients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to BAL101553 are ineligible
History of allergic reactions attributed to compounds of similar chemical or biologic composition to IPdR
Patients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to PT2385 are ineligible
History of allergic reactions attributed to compounds of similar chemical or biological composition to other agents used in this study